Viani GA, Viana BS, Martin JEC, Rossi BT, Zuliani G, Stefano EJ. Intensity‐modulated radiotherapy reduces toxicity with similar biochemical control compared with 3‐dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Cancer 2016;122(13):2004-11.
DOI: 10.1002/cncr.29983
Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, et al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. PLoS One 2016;11(5):e0154499.
DOI: 10.1371/journal.pone.0154499
Zapatero A, Roch M, Büchser D, Castro P, Fernández-Banda L, Pozo G, et al. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. Clinical and Translational Oncology 2017;19(9):1161-7.
DOI: 10.1007/s12094-017-1655-9
Bolla M, van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11(11):1066-73.
DOI: 10.1016/S1470-2045(10)70223-0
Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, et al. Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy. J Clin Oncol 2006;24(13):1990-6.
DOI: 10.1200/JCO.2005.05.2530
Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, et al. Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate. JAMA 2005;294(10):1233.
DOI: 10.1001/jama.294.10.1233
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer. Int J Rad Oncol*Biol*Physics 2008;70(1):67-74.
DOI: 10.1016/j.ijrobp.2007.06.054
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17(8):1047-60.
DOI: 10.1016/S1470-2045(16)30102-4
Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol 2017;35(17):1884-90.
DOI: 10.1200/JCO.2016.71.7397
Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 2016;17(4):464-74.
DOI: 10.1016/S1470-2045(15)00567-7
Lee WR, Dignam JJ, Amin M, Bruner DW, Low D, Swanson GP, et al. Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer. Int J Rad Oncol*Biol*Physics 2023;117(2):S3-4.
DOI: 10.1016/j.ijrobp.2023.06.209
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet 2019;394(10196):385-95.
DOI: 10.1016/S0140-6736(19)31131-6
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. The Lancet Oncol 2019;20(11):1531-43.
DOI: 10.1016/S1470-2045(19)30569-8
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet 2019;394(10196):385-95.
DOI: 10.1016/S0140-6736(19)31131-6
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019;20(11):1531-43.
DOI: 10.1016/S1470-2045(19)30569-8
van As N, Tree A, Patel J, Ostler P, Van Der Voet H, Loblaw DA, et al. 5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer. Int J Rad Oncol*Biol*Physics 2023;117(4):e2-3.
DOI: 10.1016/j.ijrobp.2023.08.027
D’Amico A V., Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer. JAMA 2008;299(3).
DOI: 10.1001/jama.299.3.289
Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, et al. Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910. J Clin Oncol 2015;33(4):332-9.
DOI: 10.1200/JCO.2014.58.0662
Zapatero A, Guerrero A, Maldonado X, Álvarez A, San-Segundo CG, Rodríguez MÁC, et al. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol 2022;23(5):671-81.
DOI: 10.1016/S1470-2045(22)00190-5
Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05). Int J Rad Oncol*Biol*Physics 2007;67(1):39-47.
DOI: 10.1016/j.ijrobp.2006.08.016
Ito K, Saito S, Yorozu A, Kojima S, Kikuchi T, Higashide S, et al. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival. Int J Clin Oncol 2018;23(6):1148-59.
DOI: 10.1007/s10147-018-1309-0
Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009;27(5):607-12.
DOI: 10.1007/s00345-009-0418-9
Giberti C, Gallo F, Schenone M, Gastaldi E, Cortese P, Ninotta G, et al. Robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer. Can J Urol 2017;24(2):8728-33.
Michalski JM, Winter KA, Prestidge BR, Sanda MG, Amin M, Bice WS, et al. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial. J Clin Oncol 2023;41(24):4035-44.
DOI: 10.1200/JCO.22.01856
Merrick GS, Wallner KE, Galbreath RW, Butler WM, Fiano R, Orio PF, et al. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials. Brachytherapy 2015;14(5):677-85.
DOI: 10.1016/j.brachy.2015.05.001
Merrick GS, Wallner KE, Galbreath RW, Butler WM, Adamovich E. Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease? Brachytherapy 2016;15(1):79-84.
DOI: 10.1016/j.brachy.2015.09.011
Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Rad Oncol*Biol*Physics 2017;98(2):275-85.
DOI: 10.1016/j.ijrobp.2016.11.026
Oh J, Tyldesley S, Pai HH, McKenzie MR, Halperin RM, Duncan GG, et al. An Updated Analysis of Survival Endpoints for ASCENDE-RT, a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Rad Oncol*Biol*Physics 2020;108(3):S62.
DOI: 10.1016/j.ijrobp.2020.07.2194
Nagore G, Moreno-Olmedo E, Suárez-Gironzini V, Aakki L, LI RG, Gómez E, et al. Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer. Radiother Oncol 2023;186:109807.
DOI: 10.1016/j.radonc.2023.109807
Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol 2017;124(1):56-60.
DOI: 10.1016/j.radonc.2017.06.014
Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012;103(2):217-22.
DOI: 10.1016/j.radonc.2012.01.007
Hoskin PJ, Rojas AM, Ostler PJ, Bryant L, Lowe GJ. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. Radiother Oncol 2021;154:214-9.
DOI: 10.1016/j.radonc.2020.09.047
Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol 2022;23(2):304-16.
DOI: 10.1016/S1470-2045(21)00705-1
Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, et al. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. JAMA Oncol 2022;8(3):e216871.
DOI: 10.1001/jamaoncol.2021.6871
Cho E, Mostaghel EA, Russell KJ, Liao JJ, Konodi MA, Kurland BF, et al. External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens. Int J Rad Oncol*Biol*Physics 2015;92(2):236-43.
DOI: 10.1016/j.ijrobp.2015.01.020
Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, et al. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. Int J Rad Oncol*Biol*Physics 2021;109(5):1271-8.
DOI: 10.1016/j.ijrobp.2020.11.059
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. The Lancet 2022;399(10323):447-60.
DOI: 10.1016/S0140-6736(21)02437-5
Sandler HM, Freedland SJ, Shore ND, Smith MR, Rosales RS, Brookman-May SD, et al. Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer. J Clin Oncol 2022;40(Suppl.16):5084-5084.
DOI: 10.1200/JCO.2022.40.16_suppl.5084
Williams S, Davis ID, Sweeney C, Stockler MR, Martin AJ, Hague W, et al. Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303). J Clin Oncol 2018;36(Suppl.6):TPS156-TPS156.
DOI: 10.1200/JCO.2018.36.6_suppl.TPS156
Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, et al. Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study. Int J Rad Oncol*Biol*Physics 2016;96(4):759-69.
DOI: 10.1016/j.ijrobp.2016.06.2455
Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol 2018;19(11):1504-15.
DOI: 10.1016/S1470-2045(18)30528-X
Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. J Clin Oncol 2021;39(11):1234-42.
DOI: 10.1200/JCO.20.03282
Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). The Lancet 2012;380(9858):2018-27.
DOI: 10.1016/S0140-6736(12)61253-7
Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. J Urol 2009;181(3):956-62.
DOI: 10.1016/j.juro.2008.11.032
Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial. Eur Urol 2014;66(2):243-50.
DOI: 10.1016/j.eururo.2014.03.011
Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. The Lancet 2020;396(10260):1413-21.
DOI: 10.1016/S0140-6736(20)31553-1
Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2020;21(10):1331-40.
DOI: 10.1016/S1470-2045(20)30456-3
Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 2020;21(10):1341-52.
DOI: 10.1016/S1470-2045(20)30454-X
Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. The Lancet 2020;396(10260):1422-31.
DOI: 10.1016/S0140-6736(20)31952-8
Parker C, Clarke N, Cook A, Kynaston H, Meidahl Petersen P, Cross W, et al. 1764O Timing of radiotherapy (RT) after radical prostatectomy (RP): Final results of RADICALS RT randomised controlled trial. Ann Oncol 2023;34:S953.
DOI: 10.1016/j.annonc.2023.09.2714
Burdett S, Fisher D, Parker CC, Sydes MR, Pommier P, Sargos P, et al. LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data. Ann Oncol 2022;33:S1428-9.
DOI: 10.1016/j.annonc.2022.08.067
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75(3):410-8.
DOI: 10.1016/j.eururo.2018.09.008
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet 2018;392(10162):2353-66.
DOI: 10.1016/S0140-6736(18)32486-3
Ali A, Hoyle A, Haran ÁM, Brawley CD, Cook A, Amos C, et al. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer. JAMA Oncol 2021;7(4):555.
DOI: 10.1001/jamaoncol.2020.7857
Bossi A, Foulon S, Maldonado X, Sargos P, McDermott RS, Flechon A, et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design. J Clin Oncol 2023;41(Suppl.17):LBA5000-LBA5000.
DOI: 10.1200/JCO.2023.41.17_suppl.LBA5000
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. J Clin Oncol 2020;38(Suppl.6):10-10.
DOI: 10.1200/JCO.2020.38.6_suppl.10
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncol 2020;6(5):650.
DOI: 10.1001/jamaoncol.2020.0147
Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol 2022;40(29):3377-82.
DOI: 10.1200/JCO.22.00644
Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer. JAMA Oncol 2023;9(6):825.
DOI: 10.1001/jamaoncol.2023.0161
Número de descargas:
3684
Número de visitas:
191
Citas:
0
